FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
|Articles|November 1, 2000
The American Journal of Managed Care
- November 2000
- Volume 6
- Issue 11
Disease Management for Diabetes Mellitus: Impact on Hemoglobin A1C
Advertisement
Articles in this issue
almost 26 years ago
Is the Gatekeeper Just Another Buggy Whip?almost 26 years ago
Show Me the Money: Medical Directors' Responses to a Mail SurveyAdvertisement
Related to this article
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Highlights Practice-Changing COPD Therapy and Strategies
4
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
5